Molecular Therapy — Methods & Clinical DevelopmentMolecular BiologyPeer-reviewed journal article
Transcriptional changes in non-human primate tissues after intrathecal delivery of serotype 9 adeno-associated viral vector: insights into organ toxicities
Fumiaki AiharaiD, Mathew Mardo, Vera M. RudaiD, Tony del Rio, Karine Bigot, Jochen SingeriD, Megumi Onishi‐Seebacher, Philippe CouttetiD, Keith Mansfield, Eloïse HudryiD
Abstract
Adeno associated virus (AAV)-based gene transfer has brought transformative therapeutic benefits to patients with otherwise untreatable genetic diseases. However, treatment-related organ toxicities, particularly for high doses, remain a safety concern in the clinic with some translatability in preclinical species. In the present study, we conducted an RNAseq analysis in non-human primates administered intrathecally with scAAV9-CBA-GFP, empty viral capsid particles, or a Promoterless vector. This analysis revealed a broad and long-lasting (4 weeks after dosing) transcriptional impact of the viral transduction/transgene expression on tissues. Liver and DRG, known to be primary sites of toxicity induced by AAV9, had the highest viral load and the most significant transcriptional changes. Our analysis revealed that most of the differentially expressed genes were upregulated, and common gene signatures belonged to immune pathways (innate and adaptive), demonstrating a persistent low-grade immune response up to four weeks post-dosing. Interestingly and across all tissues considered, the impact of empty capsids or of the Promoterless vector was minimal, suggesting that both the presence of the capsid and of a productive viral genome contributed to the observed changes. This study provides a unique insight into the transcriptional responses to AAV9 in key tissues primarily exposed by the vector.
- organism: non-human primate
- assay: bulk RNA-seq
- research focus: differential expression
- approach: statistical model
- Citations
- 1
- FWCI
- 0.59
- Field percentile
- top 32%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Loss of transgene expression limits liver gene therapy in primates
Jenny A. Greig, Kelly M. Martins, … James M. Wilson·Nature BiotechnologyPeer-reviewed·Nov 6, 2023
- In vivo selection in non-human primates identifies superior AAV capsids for on-target CSF delivery to spinal cord
K. S. Hanlon, M. Cheng, … C. A. Maguire·bioRxiv·Sep 13, 2023
- Novel Engineered AAV Variants Demonstrate Superior Blood-Brain Barrier Penetration and Safety in Non-Human Primates
Zhenhua Wang, Hao Li, … Zhenming An·bioRxiv·Apr 1, 2026
- AAV-DJ is Superior to AAV9 for Targeting Brain and Spinal Cord, and De-Targeting Liver Across Multiple Delivery Routes in Mice
Monika Chauhan, Audrey L. Daugherty, … Christina A. Pacak·Journal of Translational MedicinePeer-reviewed·Sep 5, 2024
- Systemic and local immune response to intraocular AAV vector administration in non-human primates
D. Ail, D. Ren, … D. Dalkara·bioRxiv·Sep 13, 2021
- AAV Capsid Screening for Translational Pig Research Using a Mouse Xenograft Liver Model
Melanie Willimann, Amita Tiyaboonchai, … Beat Thöny·bioRxiv·May 29, 2024